VCA Stocks

Gemin X Pharmaceuticals, Inc., a privately held pharmaceutical company focused on developing novel treatments for cancer, today announced the closing of a $38 million tranched Series C financing.  Gemin X’s lead product, obatoclax (GX15-070), a small molecule, pan Bcl-2 inhibitor, is currently in Phase 2 clinical trials in both hematological and solid tumor cancers. Gemin X’s second compound GMX1777, is a potent, small molecule that specifically inhibits nicotinamide phosphoribosyl transferase (NAMPRT), resulting in cancer cell death independently of the tumor suppressor p53. It is currently in a Phase 1 clinical trial in patients with refractory solid tumors and lymphomas.